

ADVANCED HEALTH INTELLIGENCE LTD

Appendix 4D Half-year report for the half-year ended 31 December 2023

Name of entity: **ADVANCED HEALTH INTELLIGENCE LTD**
ACN: **602 111 115**
Current Reporting Period **Half Year ended 31 December 2023**
Previous Reporting period **Half Year ended 31 December 2022**

Results for announcement to the market.

Item 1

Operating Performance	6 months ending			
	31 Dec 2023 A\$	31 Dec 2022 A\$	Movement A\$	Movement %
Revenue from continuing activities	264,170	1,829,708	(1,565,538)	-85.6%
Profit/(loss) from continuing activities after income tax	(7,735,029)	(3,906,271)	(3,828,758)	98%
Total comprehensive loss for the half year attributable to members	(7,960,050)	(3,898,924)	(4,061,126)	104.2%

Item 2

Dividends
It is not proposed to pay dividends.
There are no dividend or distribution reinvestment plans in operation and there has been no dividend or distribution payments during the financial half year ended 31 December 2023.

Item 3 – Brief Explanation

Revenue from continuing activities for the current period includes operating and other revenue, as well as finance income of \$113,812.

The net loss after income tax for the half year was \$7,735,029 (2022: \$3,906,271).

The consolidated entity generated operating revenue of \$122,457 for the half-year ended 31 December 2023 (2022 - \$357,914). Software income for the period was down \$23,984 to \$93,520 (2022 - \$117,504). The decline is primarily attributable to a decrease in income from software development kits, primarily as a result of the company refocusing its development and customer activities towards the launch of the Company's Biometric Health Assessment (BHA) product, and existing commercial partners preparing launch of their own platforms that utilise AHI's technology.

Comparatives for 2022 have been restated to include Grant Income of \$1,298,929.

Item 4

Net Tangible Assets	6 months ending			
	31 Dec 2023	31 Dec 2022	Movement	Movement
	\$	\$	\$	%
Net tangible assets/(liabilities) per security	(0.031)	0.008	(0.039)	-484.11%

Item 5

Control gained or lost over Entities during the period
No control was gained or lost over subsidiary entities during the period

Item 6

Details of joint venture and associated entities
Not applicable

Item 7

Accounting Standards
The financial report has been prepared in accordance with Australian Equivalents to International Financial Reporting Standards.

Item 8

Auditor's review report
Our half-year report is based on the financial report of Advanced Health Intelligence Ltd for the half year ended 31 December 2023, which has been reviewed by PKF Brisbane Audit. Refer to the 31 December 2023 half-year financial report for the independent auditor's review report provided to the members of Advanced Health Intelligence Ltd. PKF Brisbane Audit's review report includes a Material Uncertainty in Relation to Going Concern and an Emphasis of Matter regarding Estimation Uncertainty in the Preparation of the Financial Report.

Appendix 4D Requirements	Reference
1. Reporting period and the previous corresponding period.	Refer to page 1 of this report.
2. Results for announcement to the market.	Refer to page 1 of this report "Results for announcement to the market" and Items 1, 2 and 3 of this report.
3. Net tangible assets per security.	Refer to Item 4 of this report.
4. Details of entities where control has been gained or lost during the period.	Refer to Item 5 of this report.
5. Details of individual and total dividends or distributions and dividend or distribution payments.	Refer to Item 2 of this report.
6. Details of dividend or distribution reinvestment plans in operation and the last date for the receipt of an election notice for participation in a dividend or distribution reinvestment plan.	Refer to Item 2 of this report.
7. Details of joint venture and associated entities.	Refer to Item 6 of this report.
8. For foreign entities, accounting standards used in compiling reports.	Not applicable.
9. If the accounts are subject to audit dispute or qualification, a description of the dispute or qualification.	Refer to Item 8 of this report.